Skip to main content
Article thumbnail
Location of Repository

Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B

By Reinaldo Menezes Martins, Gilberta Bensabath, Luiz Claudio Arraes, Maria de Lourdes Aguiar Oliveira, Juliana Custódio Miguel, Glayse Glayde Barbosa and Luiz Antonio Bastos Camacho

Abstract

The immunogenicity and safety of a new recombinant hepatitis B vaccine from the Instituto Butantan (Butang®) were evaluated in a multicenter, double-blind, prospective equivalence study in three centers in Brazil. Engerix B® was the standard vaccine. A total of 3937 subjects were recruited and 2754 (70%) met all protocol criteria at the end of the study. All the subjects were considered healthy and denied having received hepatitis B vaccine before the study. Study subjects who adhered to the protocol were newborn infants (566), children 1 to 10 years old (484), adolescents from 11 to 19 years (740), adults from 20 to 30 years (568), and adults from 31 to 40 years (396). Vaccine was administered in three doses on the schedule 0, 1, and 6 months (newborn infants, adolescents, and adults) or 0, 1, and 7 months (children). Vaccine dose was intramuscular 10 µg (infants, children, and adolescents) or 20 µg (adults). Percent seroprotection (assumed when anti-HBs titers were > 10mIU/ml) and geometric mean titer (mIU/ml) were: newborn infants, 93.7% and 351.1 (Butang®) and 97.5% and 1530.6 (Engerix B®); children, 100% and 3600.0 (Butang®) and 97.7% and 2753.1 (Engerix B®); adolescents, 95.1% and 746.3 (Butang®) and 96% and 1284.3 (Engerix B®); adults 20-30 years old, 91.8% and 453.5 (Butang®) and 95.5% and 1369.0 (Engerix B®); and adults 31-40 years old, 79.8% and 122.7 (Butang®) and 92.4% and 686.2 (Engerix B®). There were no severe adverse events following either vaccine. The study concluded that Butang® was equivalent to Engerix B® in children, and less immunogenic but acceptable for use in newborn infants, adolescents, and young adults

Topics: hepatitis B vaccine, recombinant vaccines, immunization, Microbiology, QR1-502, Science, Q, DOAJ:Microbiology, DOAJ:Biology, DOAJ:Biology and Life Sciences, Arctic medicine. Tropical medicine, RC955-962, Special situations and conditions, RC952-1245, Internal medicine, RC31-1245, Medicine, R, DOAJ:Internal medicine, DOAJ:Medicine (General), DOAJ:Health Sciences
Publisher: Instituto Oswaldo Cruz, Ministério da Saúde
Year: 2004
DOI identifier: 10.1590/S0074-02762004000800014
OAI identifier: oai:doaj.org/article:287c6695e6fc468ab7fd545d1dd2327e
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1678-8060 (external link)
  • https://doaj.org/toc/0074-0276 (external link)
  • http://www.scielo.br/scielo.ph... (external link)
  • https://doaj.org/article/287c6... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.